GGT1 and melanoma: The specific ability of GGT1 to cleave the gamma-glutamyl residue can in fact be exploited to activate glutathionylated pro-drugs, a pharmacologic strategy whose efficacy was documented in melanoma cells treated with the anti-angiogenic agent GSAO (18).